Astria Therapeutics Inc (NAS:ATXS)

$ 9.17 -0.11 (-1.19%) Market Cap: 503.55 Mil Enterprise Value: 235.18 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 36/100

Q3 2023 Astria Therapeutics Inc Earnings Call Transcript
Nov 13, 2023

$4.49 (-2.39%)

Earnings
Astria Therapeutics Inc to Discuss the OX40 Program STAR-0310 Call Transcript
Oct 12, 2023
Astria Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q4 2022 Astria Therapeutics Inc Earnings Call Transcript
Mar 22, 2023

$11.33 (+0.98%)

Earnings
Astria Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Astria Therapeutics Inc Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 Transcript
Dec 15, 2022
Astria Therapeutics Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Astria Therapeutics Inc R&D Day: Update On STAR-0215 And Its Clinical Development For The Prevention Of HAE Attacks Transcript
Sep 30, 2022
Q3 2021 Astria Therapeutics Inc Earnings Call Transcript
Nov 10, 2021

$7.07 (+0.86%)

Earnings
Catabasis Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 13, 2021
Catabasis Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 02, 2021
Catabasis Pharmaceuticals Inc Acquisition of Quellis Biosciences Inc Call Transcript
Jan 29, 2021
Catabasis Pharmaceuticals, Inc. - Special Call Transcript
Sep 11, 2020
Q4 2019 Catabasis Pharmaceuticals Inc Earnings Call Transcript
Mar 10, 2020

$28.74 (+1.91%)

Earnings
Q3 2019 Catabasis Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2019

$31.74 (+1.93%)

Earnings
Q2 2019 Catabasis Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2019

$39.66 (+1.85%)

Earnings
Q1 2019 Catabasis Pharmaceuticals Inc Earnings Call Transcript
May 14, 2019

$47.46 (+4.91%)

Earnings
Q4 2018 Catabasis Pharmaceuticals Inc Earnings Call Transcript
Mar 14, 2019

$34.8 (+3.57%)

Earnings

Astria Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 06:00PM GMT

Release Date Price: $11.68 (-6.93%)

Transcript

Eun Yang

Jefferies - Analyst

So, next presenting company is Astria. We are going to be having a fire-side chat. But before we begin, Jill, would you like to give us a kind of a quick overview? Then we can go into Q&As.

Jill Milne

Astria Therapeutics, Inc. - Co-Founder & CEO

That sounds great. Thanks, Eun. So, I'll start by saying, during our remarks today, we will make statements related to our business based on current and future expectations that may be considered forward-looking statements under applicable securities laws.

So, with that, I will advance to the next slide. So, at Astria Therapeutics, we are developing therapeutics to treat patients affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of an enzyme called plasma kallikrein. Plasma kallikrein is a clinically and commercially validated target for the treatment of hereditary angioedema, or HAE.

HAE is a severe, rare disease. It is truly a life-changing diagnosis for those people who are affected

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.